nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2B6—malignant glioma	0.342	0.54	CbGaD
Citalopram—SLC6A3—malignant glioma	0.291	0.46	CbGaD
Citalopram—CYP1A2—Carmustine—malignant glioma	0.0728	0.57	CbGbCtD
Citalopram—CYP3A4—Temozolomide—malignant glioma	0.055	0.431	CbGbCtD
Citalopram—HTR2C—choroid plexus—malignant glioma	0.0116	0.259	CbGeAlD
Citalopram—Escitalopram—SLC6A3—malignant glioma	0.0038	1	CrCbGaD
Citalopram—SLC6A3—telencephalic ventricle—malignant glioma	0.00351	0.0785	CbGeAlD
Citalopram—HTR2C—telencephalic ventricle—malignant glioma	0.00339	0.0759	CbGeAlD
Citalopram—SLC6A3—brainstem—malignant glioma	0.000949	0.0212	CbGeAlD
Citalopram—HTR2C—brainstem—malignant glioma	0.000918	0.0205	CbGeAlD
Citalopram—SLC6A4—brainstem—malignant glioma	0.00087	0.0195	CbGeAlD
Citalopram—SLC6A3—telencephalon—malignant glioma	0.000843	0.0189	CbGeAlD
Citalopram—HTR2C—telencephalon—malignant glioma	0.000815	0.0182	CbGeAlD
Citalopram—SLC6A4—telencephalon—malignant glioma	0.000772	0.0173	CbGeAlD
Citalopram—CHRM1—telencephalon—malignant glioma	0.000769	0.0172	CbGeAlD
Citalopram—SLC6A2—brainstem—malignant glioma	0.000766	0.0171	CbGeAlD
Citalopram—ADRA1A—brainstem—malignant glioma	0.000712	0.0159	CbGeAlD
Citalopram—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000688	0.00519	CcSEcCtD
Citalopram—Endocrine disorder—Temozolomide—malignant glioma	0.000683	0.00515	CcSEcCtD
Citalopram—Speech disorder—Carmustine—malignant glioma	0.000681	0.00514	CcSEcCtD
Citalopram—SLC6A2—telencephalon—malignant glioma	0.00068	0.0152	CbGeAlD
Citalopram—Accidental injury—Carmustine—malignant glioma	0.000662	0.005	CcSEcCtD
Citalopram—Speech disorder—Temozolomide—malignant glioma	0.000658	0.00497	CcSEcCtD
Citalopram—Disturbance in attention—Temozolomide—malignant glioma	0.000654	0.00493	CcSEcCtD
Citalopram—Breast pain—Temozolomide—malignant glioma	0.000649	0.0049	CcSEcCtD
Citalopram—Amenorrhoea—Temozolomide—malignant glioma	0.000644	0.00486	CcSEcCtD
Citalopram—Thinking abnormal—Carmustine—malignant glioma	0.00064	0.00483	CcSEcCtD
Citalopram—HTR2C—medulla oblongata—malignant glioma	0.00064	0.0143	CbGeAlD
Citalopram—ADRA1A—telencephalon—malignant glioma	0.000632	0.0141	CbGeAlD
Citalopram—Drug interaction—Carmustine—malignant glioma	0.000632	0.00476	CcSEcCtD
Citalopram—Viral infection—Temozolomide—malignant glioma	0.000627	0.00473	CcSEcCtD
Citalopram—Leukocytosis—Carmustine—malignant glioma	0.000623	0.0047	CcSEcCtD
Citalopram—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000623	0.0047	CcSEcCtD
Citalopram—Herpes simplex—Temozolomide—malignant glioma	0.000614	0.00463	CcSEcCtD
Citalopram—SLC6A3—midbrain—malignant glioma	0.000605	0.0135	CbGeAlD
Citalopram—Gait disturbance—Carmustine—malignant glioma	0.0006	0.00453	CcSEcCtD
Citalopram—Hepatic enzyme increased—Temozolomide—malignant glioma	0.000599	0.00452	CcSEcCtD
Citalopram—Coordination abnormal—Carmustine—malignant glioma	0.000597	0.0045	CcSEcCtD
Citalopram—Neck pain—Carmustine—malignant glioma	0.000593	0.00447	CcSEcCtD
Citalopram—SLC6A3—spinal cord—malignant glioma	0.00059	0.0132	CbGeAlD
Citalopram—Pulmonary embolism—Carmustine—malignant glioma	0.000586	0.00442	CcSEcCtD
Citalopram—HTR2C—midbrain—malignant glioma	0.000585	0.0131	CbGeAlD
Citalopram—Gait disturbance—Temozolomide—malignant glioma	0.00058	0.00438	CcSEcCtD
Citalopram—Coordination abnormal—Temozolomide—malignant glioma	0.000577	0.00435	CcSEcCtD
Citalopram—Musculoskeletal pain—Temozolomide—malignant glioma	0.000573	0.00432	CcSEcCtD
Citalopram—HTR2C—spinal cord—malignant glioma	0.000571	0.0128	CbGeAlD
Citalopram—Vaginal inflammation—Temozolomide—malignant glioma	0.000566	0.00427	CcSEcCtD
Citalopram—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000566	0.00427	CcSEcCtD
Citalopram—Pulmonary embolism—Temozolomide—malignant glioma	0.000566	0.00427	CcSEcCtD
Citalopram—Urinary incontinence—Carmustine—malignant glioma	0.000566	0.00427	CcSEcCtD
Citalopram—Depressed level of consciousness—Carmustine—malignant glioma	0.000566	0.00427	CcSEcCtD
Citalopram—Candida infection—Carmustine—malignant glioma	0.000559	0.00422	CcSEcCtD
Citalopram—SLC6A4—midbrain—malignant glioma	0.000555	0.0124	CbGeAlD
Citalopram—ABCB1—blood vessel—malignant glioma	0.000552	0.0123	CbGeAlD
Citalopram—Neuropathy—Carmustine—malignant glioma	0.00055	0.00415	CcSEcCtD
Citalopram—Influenza like illness—Temozolomide—malignant glioma	0.00055	0.00415	CcSEcCtD
Citalopram—Urinary incontinence—Temozolomide—malignant glioma	0.000547	0.00412	CcSEcCtD
Citalopram—Depressed level of consciousness—Temozolomide—malignant glioma	0.000547	0.00412	CcSEcCtD
Citalopram—SLC6A4—spinal cord—malignant glioma	0.000541	0.0121	CbGeAlD
Citalopram—Candida infection—Temozolomide—malignant glioma	0.000541	0.00408	CcSEcCtD
Citalopram—Coma—Carmustine—malignant glioma	0.000535	0.00404	CcSEcCtD
Citalopram—Vaginal infection—Temozolomide—malignant glioma	0.000535	0.00403	CcSEcCtD
Citalopram—SLC6A2—medulla oblongata—malignant glioma	0.000534	0.0119	CbGeAlD
Citalopram—Neuropathy—Temozolomide—malignant glioma	0.000532	0.00401	CcSEcCtD
Citalopram—Aplastic anaemia—Temozolomide—malignant glioma	0.000532	0.00401	CcSEcCtD
Citalopram—Neoplasm—Carmustine—malignant glioma	0.00053	0.004	CcSEcCtD
Citalopram—Gynaecomastia—Carmustine—malignant glioma	0.000524	0.00395	CcSEcCtD
Citalopram—Dry eye—Temozolomide—malignant glioma	0.000523	0.00395	CcSEcCtD
Citalopram—Neoplasm—Temozolomide—malignant glioma	0.000512	0.00386	CcSEcCtD
Citalopram—Abnormal vision—Carmustine—malignant glioma	0.000511	0.00385	CcSEcCtD
Citalopram—Mental disability—Carmustine—malignant glioma	0.000508	0.00384	CcSEcCtD
Citalopram—Sepsis—Carmustine—malignant glioma	0.000508	0.00384	CcSEcCtD
Citalopram—Abnormal vision—Temozolomide—malignant glioma	0.000494	0.00373	CcSEcCtD
Citalopram—Phlebitis—Carmustine—malignant glioma	0.000494	0.00372	CcSEcCtD
Citalopram—Mental disability—Temozolomide—malignant glioma	0.000491	0.00371	CcSEcCtD
Citalopram—HRH1—telencephalon—malignant glioma	0.000489	0.0109	CbGeAlD
Citalopram—Diabetes mellitus—Carmustine—malignant glioma	0.000489	0.00369	CcSEcCtD
Citalopram—Ear pain—Temozolomide—malignant glioma	0.000482	0.00363	CcSEcCtD
Citalopram—SLC6A3—central nervous system—malignant glioma	0.000479	0.0107	CbGeAlD
Citalopram—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000473	0.00356	CcSEcCtD
Citalopram—Eye pain—Carmustine—malignant glioma	0.000471	0.00355	CcSEcCtD
Citalopram—CYP2E1—telencephalon—malignant glioma	0.00047	0.0105	CbGeAlD
Citalopram—SLC6A3—cerebellum—malignant glioma	0.000468	0.0105	CbGeAlD
Citalopram—Gastroenteritis—Temozolomide—malignant glioma	0.000464	0.0035	CcSEcCtD
Citalopram—HTR2C—central nervous system—malignant glioma	0.000463	0.0104	CbGeAlD
Citalopram—Injury—Carmustine—malignant glioma	0.000463	0.00349	CcSEcCtD
Citalopram—Vascular purpura—Temozolomide—malignant glioma	0.000459	0.00347	CcSEcCtD
Citalopram—Deafness—Temozolomide—malignant glioma	0.000459	0.00347	CcSEcCtD
Citalopram—Hepatic failure—Temozolomide—malignant glioma	0.000457	0.00345	CcSEcCtD
Citalopram—Eye pain—Temozolomide—malignant glioma	0.000455	0.00343	CcSEcCtD
Citalopram—Amnesia—Carmustine—malignant glioma	0.000453	0.00342	CcSEcCtD
Citalopram—Nasal congestion—Temozolomide—malignant glioma	0.000451	0.0034	CcSEcCtD
Citalopram—Hot flush—Temozolomide—malignant glioma	0.000439	0.00331	CcSEcCtD
Citalopram—SLC6A4—central nervous system—malignant glioma	0.000439	0.00982	CbGeAlD
Citalopram—Amnesia—Temozolomide—malignant glioma	0.000437	0.0033	CcSEcCtD
Citalopram—CHRM1—central nervous system—malignant glioma	0.000437	0.00978	CbGeAlD
Citalopram—Menopausal symptoms—Temozolomide—malignant glioma	0.000436	0.00329	CcSEcCtD
Citalopram—Thirst—Temozolomide—malignant glioma	0.000432	0.00326	CcSEcCtD
Citalopram—Hyponatraemia—Carmustine—malignant glioma	0.000427	0.00322	CcSEcCtD
Citalopram—Purpura—Temozolomide—malignant glioma	0.000426	0.00322	CcSEcCtD
Citalopram—Diplopia—Carmustine—malignant glioma	0.000425	0.00321	CcSEcCtD
Citalopram—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000425	0.00321	CcSEcCtD
Citalopram—CYP2D6—brainstem—malignant glioma	0.000419	0.00938	CbGeAlD
Citalopram—Diplopia—Temozolomide—malignant glioma	0.000411	0.0031	CcSEcCtD
Citalopram—Face oedema—Carmustine—malignant glioma	0.000411	0.0031	CcSEcCtD
Citalopram—Affect lability—Temozolomide—malignant glioma	0.000405	0.00305	CcSEcCtD
Citalopram—Ataxia—Carmustine—malignant glioma	0.0004	0.00302	CcSEcCtD
Citalopram—Face oedema—Temozolomide—malignant glioma	0.000397	0.00299	CcSEcCtD
Citalopram—Liver function test abnormal—Carmustine—malignant glioma	0.000393	0.00296	CcSEcCtD
Citalopram—Mood swings—Temozolomide—malignant glioma	0.000389	0.00294	CcSEcCtD
Citalopram—Hypokalaemia—Carmustine—malignant glioma	0.000387	0.00292	CcSEcCtD
Citalopram—Ataxia—Temozolomide—malignant glioma	0.000386	0.00292	CcSEcCtD
Citalopram—SLC6A2—central nervous system—malignant glioma	0.000386	0.00864	CbGeAlD
Citalopram—Dehydration—Temozolomide—malignant glioma	0.000382	0.00288	CcSEcCtD
Citalopram—SLC6A3—brain—malignant glioma	0.00038	0.00851	CbGeAlD
Citalopram—Dry skin—Temozolomide—malignant glioma	0.000377	0.00284	CcSEcCtD
Citalopram—Muscular weakness—Carmustine—malignant glioma	0.000375	0.00283	CcSEcCtD
Citalopram—Hypokalaemia—Temozolomide—malignant glioma	0.000374	0.00282	CcSEcCtD
Citalopram—CYP2D6—telencephalon—malignant glioma	0.000372	0.00833	CbGeAlD
Citalopram—Breast disorder—Temozolomide—malignant glioma	0.000371	0.0028	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00037	0.00279	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.00037	0.00279	CcSEcCtD
Citalopram—CYP2E1—medulla oblongata—malignant glioma	0.000369	0.00826	CbGeAlD
Citalopram—Dysphagia—Carmustine—malignant glioma	0.000368	0.00277	CcSEcCtD
Citalopram—HTR2C—brain—malignant glioma	0.000368	0.00822	CbGeAlD
Citalopram—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000363	0.00273	CcSEcCtD
Citalopram—Muscular weakness—Temozolomide—malignant glioma	0.000363	0.00273	CcSEcCtD
Citalopram—ADRA1A—central nervous system—malignant glioma	0.000359	0.00804	CbGeAlD
Citalopram—Abdominal distension—Temozolomide—malignant glioma	0.000358	0.0027	CcSEcCtD
Citalopram—Dysphagia—Temozolomide—malignant glioma	0.000355	0.00268	CcSEcCtD
Citalopram—ADRA1A—cerebellum—malignant glioma	0.000351	0.00785	CbGeAlD
Citalopram—Pancytopenia—Carmustine—malignant glioma	0.000349	0.00263	CcSEcCtD
Citalopram—SLC6A4—brain—malignant glioma	0.000348	0.0078	CbGeAlD
Citalopram—CHRM1—brain—malignant glioma	0.000347	0.00777	CbGeAlD
Citalopram—Sweating increased—Temozolomide—malignant glioma	0.000346	0.00261	CcSEcCtD
Citalopram—Bronchitis—Temozolomide—malignant glioma	0.000342	0.00258	CcSEcCtD
Citalopram—Pancytopenia—Temozolomide—malignant glioma	0.000337	0.00254	CcSEcCtD
Citalopram—Dysuria—Temozolomide—malignant glioma	0.000332	0.00251	CcSEcCtD
Citalopram—Hyperglycaemia—Carmustine—malignant glioma	0.000332	0.0025	CcSEcCtD
Citalopram—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00033	0.00249	CcSEcCtD
Citalopram—Pneumonia—Carmustine—malignant glioma	0.00033	0.00249	CcSEcCtD
Citalopram—CYP2E1—spinal cord—malignant glioma	0.000329	0.00737	CbGeAlD
Citalopram—ABCB1—embryo—malignant glioma	0.000329	0.00737	CbGeAlD
Citalopram—Pollakiuria—Temozolomide—malignant glioma	0.000328	0.00248	CcSEcCtD
Citalopram—Erectile dysfunction—Temozolomide—malignant glioma	0.000327	0.00247	CcSEcCtD
Citalopram—Depression—Carmustine—malignant glioma	0.000327	0.00247	CcSEcCtD
Citalopram—Photosensitivity reaction—Temozolomide—malignant glioma	0.000324	0.00245	CcSEcCtD
Citalopram—Weight increased—Temozolomide—malignant glioma	0.000323	0.00244	CcSEcCtD
Citalopram—Weight decreased—Temozolomide—malignant glioma	0.000321	0.00242	CcSEcCtD
Citalopram—Neuropathy peripheral—Carmustine—malignant glioma	0.000321	0.00242	CcSEcCtD
Citalopram—Hyperglycaemia—Temozolomide—malignant glioma	0.00032	0.00242	CcSEcCtD
Citalopram—Stomatitis—Carmustine—malignant glioma	0.000319	0.00241	CcSEcCtD
Citalopram—Urinary tract infection—Carmustine—malignant glioma	0.000319	0.0024	CcSEcCtD
Citalopram—Pneumonia—Temozolomide—malignant glioma	0.000319	0.0024	CcSEcCtD
Citalopram—Infestation NOS—Temozolomide—malignant glioma	0.000317	0.00239	CcSEcCtD
Citalopram—Infestation—Temozolomide—malignant glioma	0.000317	0.00239	CcSEcCtD
Citalopram—Depression—Temozolomide—malignant glioma	0.000316	0.00238	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000314	0.00237	CcSEcCtD
Citalopram—Neuropathy peripheral—Temozolomide—malignant glioma	0.00031	0.00234	CcSEcCtD
Citalopram—Stomatitis—Temozolomide—malignant glioma	0.000309	0.00233	CcSEcCtD
Citalopram—Urinary tract infection—Temozolomide—malignant glioma	0.000308	0.00232	CcSEcCtD
Citalopram—SLC6A2—brain—malignant glioma	0.000307	0.00686	CbGeAlD
Citalopram—Hepatobiliary disease—Temozolomide—malignant glioma	0.0003	0.00226	CcSEcCtD
Citalopram—Sinusitis—Temozolomide—malignant glioma	0.000297	0.00224	CcSEcCtD
Citalopram—Haemoglobin—Carmustine—malignant glioma	0.000296	0.00223	CcSEcCtD
Citalopram—Haemorrhage—Carmustine—malignant glioma	0.000294	0.00222	CcSEcCtD
Citalopram—Hallucination—Carmustine—malignant glioma	0.000293	0.00221	CcSEcCtD
Citalopram—Hypoaesthesia—Carmustine—malignant glioma	0.000293	0.00221	CcSEcCtD
Citalopram—ABCB1—retina—malignant glioma	0.000291	0.00651	CbGeAlD
Citalopram—Oedema peripheral—Carmustine—malignant glioma	0.00029	0.00219	CcSEcCtD
Citalopram—Connective tissue disorder—Carmustine—malignant glioma	0.000289	0.00218	CcSEcCtD
Citalopram—Haemoglobin—Temozolomide—malignant glioma	0.000286	0.00216	CcSEcCtD
Citalopram—ADRA1A—brain—malignant glioma	0.000285	0.00638	CbGeAlD
Citalopram—CYP2B6—central nervous system—malignant glioma	0.000285	0.00637	CbGeAlD
Citalopram—Hepatitis—Temozolomide—malignant glioma	0.000284	0.00215	CcSEcCtD
Citalopram—Haemorrhage—Temozolomide—malignant glioma	0.000284	0.00215	CcSEcCtD
Citalopram—Visual impairment—Carmustine—malignant glioma	0.000284	0.00214	CcSEcCtD
Citalopram—Hypoaesthesia—Temozolomide—malignant glioma	0.000283	0.00213	CcSEcCtD
Citalopram—Hallucination—Temozolomide—malignant glioma	0.000283	0.00213	CcSEcCtD
Citalopram—Pharyngitis—Temozolomide—malignant glioma	0.000282	0.00213	CcSEcCtD
Citalopram—Urinary tract disorder—Temozolomide—malignant glioma	0.000281	0.00212	CcSEcCtD
Citalopram—Oedema peripheral—Temozolomide—malignant glioma	0.00028	0.00211	CcSEcCtD
Citalopram—Connective tissue disorder—Temozolomide—malignant glioma	0.000279	0.00211	CcSEcCtD
Citalopram—Urethral disorder—Temozolomide—malignant glioma	0.000279	0.0021	CcSEcCtD
Citalopram—HRH1—central nervous system—malignant glioma	0.000278	0.00622	CbGeAlD
Citalopram—Eye disorder—Carmustine—malignant glioma	0.000275	0.00207	CcSEcCtD
Citalopram—Visual impairment—Temozolomide—malignant glioma	0.000274	0.00207	CcSEcCtD
Citalopram—Flushing—Carmustine—malignant glioma	0.000273	0.00206	CcSEcCtD
Citalopram—Erythema multiforme—Temozolomide—malignant glioma	0.000269	0.00203	CcSEcCtD
Citalopram—ABCB1—telencephalon—malignant glioma	0.000268	0.00599	CbGeAlD
Citalopram—CYP2E1—central nervous system—malignant glioma	0.000267	0.00598	CbGeAlD
Citalopram—Eye disorder—Temozolomide—malignant glioma	0.000266	0.002	CcSEcCtD
Citalopram—Tinnitus—Temozolomide—malignant glioma	0.000265	0.002	CcSEcCtD
Citalopram—Flushing—Temozolomide—malignant glioma	0.000264	0.00199	CcSEcCtD
Citalopram—Cardiac disorder—Temozolomide—malignant glioma	0.000264	0.00199	CcSEcCtD
Citalopram—Arrhythmia—Carmustine—malignant glioma	0.000263	0.00198	CcSEcCtD
Citalopram—CYP2E1—cerebellum—malignant glioma	0.000261	0.00584	CbGeAlD
Citalopram—Alopecia—Carmustine—malignant glioma	0.00026	0.00196	CcSEcCtD
Citalopram—Angiopathy—Temozolomide—malignant glioma	0.000258	0.00195	CcSEcCtD
Citalopram—Mental disorder—Carmustine—malignant glioma	0.000258	0.00194	CcSEcCtD
Citalopram—Immune system disorder—Temozolomide—malignant glioma	0.000257	0.00194	CcSEcCtD
Citalopram—Mediastinal disorder—Temozolomide—malignant glioma	0.000256	0.00193	CcSEcCtD
Citalopram—Erythema—Carmustine—malignant glioma	0.000256	0.00193	CcSEcCtD
Citalopram—Malnutrition—Carmustine—malignant glioma	0.000256	0.00193	CcSEcCtD
Citalopram—Chills—Temozolomide—malignant glioma	0.000255	0.00192	CcSEcCtD
Citalopram—Alopecia—Temozolomide—malignant glioma	0.000251	0.0019	CcSEcCtD
Citalopram—Mental disorder—Temozolomide—malignant glioma	0.000249	0.00188	CcSEcCtD
Citalopram—Back pain—Carmustine—malignant glioma	0.000248	0.00187	CcSEcCtD
Citalopram—Erythema—Temozolomide—malignant glioma	0.000248	0.00187	CcSEcCtD
Citalopram—Malnutrition—Temozolomide—malignant glioma	0.000248	0.00187	CcSEcCtD
Citalopram—Dysgeusia—Temozolomide—malignant glioma	0.000242	0.00183	CcSEcCtD
Citalopram—Vision blurred—Carmustine—malignant glioma	0.000241	0.00182	CcSEcCtD
Citalopram—Tremor—Carmustine—malignant glioma	0.00024	0.00181	CcSEcCtD
Citalopram—Back pain—Temozolomide—malignant glioma	0.000239	0.00181	CcSEcCtD
Citalopram—Anaemia—Carmustine—malignant glioma	0.000237	0.00179	CcSEcCtD
Citalopram—Agitation—Carmustine—malignant glioma	0.000235	0.00178	CcSEcCtD
Citalopram—Vision blurred—Temozolomide—malignant glioma	0.000233	0.00176	CcSEcCtD
Citalopram—Tremor—Temozolomide—malignant glioma	0.000232	0.00175	CcSEcCtD
Citalopram—Ill-defined disorder—Temozolomide—malignant glioma	0.00023	0.00173	CcSEcCtD
Citalopram—Leukopenia—Carmustine—malignant glioma	0.000229	0.00173	CcSEcCtD
Citalopram—Anaemia—Temozolomide—malignant glioma	0.000229	0.00173	CcSEcCtD
Citalopram—Agitation—Temozolomide—malignant glioma	0.000227	0.00172	CcSEcCtD
Citalopram—Angioedema—Temozolomide—malignant glioma	0.000226	0.00171	CcSEcCtD
Citalopram—CYP2B6—brain—malignant glioma	0.000226	0.00506	CbGeAlD
Citalopram—Malaise—Temozolomide—malignant glioma	0.000223	0.00168	CcSEcCtD
Citalopram—Vertigo—Temozolomide—malignant glioma	0.000222	0.00168	CcSEcCtD
Citalopram—Convulsion—Carmustine—malignant glioma	0.000222	0.00167	CcSEcCtD
Citalopram—Leukopenia—Temozolomide—malignant glioma	0.000222	0.00167	CcSEcCtD
Citalopram—Hypertension—Carmustine—malignant glioma	0.000221	0.00167	CcSEcCtD
Citalopram—HRH1—brain—malignant glioma	0.000221	0.00494	CbGeAlD
Citalopram—Palpitations—Temozolomide—malignant glioma	0.000219	0.00165	CcSEcCtD
Citalopram—Myalgia—Carmustine—malignant glioma	0.000218	0.00165	CcSEcCtD
Citalopram—Chest pain—Carmustine—malignant glioma	0.000218	0.00165	CcSEcCtD
Citalopram—Anxiety—Carmustine—malignant glioma	0.000217	0.00164	CcSEcCtD
Citalopram—Cough—Temozolomide—malignant glioma	0.000216	0.00163	CcSEcCtD
Citalopram—CYP3A4—central nervous system—malignant glioma	0.000215	0.00481	CbGeAlD
Citalopram—Convulsion—Temozolomide—malignant glioma	0.000214	0.00162	CcSEcCtD
Citalopram—Hypertension—Temozolomide—malignant glioma	0.000214	0.00161	CcSEcCtD
Citalopram—CYP2E1—brain—malignant glioma	0.000212	0.00475	CbGeAlD
Citalopram—CYP2D6—central nervous system—malignant glioma	0.000212	0.00473	CbGeAlD
Citalopram—Confusional state—Carmustine—malignant glioma	0.000211	0.00159	CcSEcCtD
Citalopram—Myalgia—Temozolomide—malignant glioma	0.000211	0.00159	CcSEcCtD
Citalopram—Arthralgia—Temozolomide—malignant glioma	0.000211	0.00159	CcSEcCtD
Citalopram—ABCB1—medulla oblongata—malignant glioma	0.00021	0.00471	CbGeAlD
Citalopram—Anxiety—Temozolomide—malignant glioma	0.00021	0.00158	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000209	0.00158	CcSEcCtD
Citalopram—Oedema—Carmustine—malignant glioma	0.000209	0.00158	CcSEcCtD
Citalopram—Discomfort—Temozolomide—malignant glioma	0.000208	0.00157	CcSEcCtD
Citalopram—Infection—Carmustine—malignant glioma	0.000208	0.00157	CcSEcCtD
Citalopram—CYP2D6—cerebellum—malignant glioma	0.000207	0.00463	CbGeAlD
Citalopram—Dry mouth—Temozolomide—malignant glioma	0.000206	0.00155	CcSEcCtD
Citalopram—Thrombocytopenia—Carmustine—malignant glioma	0.000205	0.00154	CcSEcCtD
Citalopram—Tachycardia—Carmustine—malignant glioma	0.000204	0.00154	CcSEcCtD
Citalopram—Confusional state—Temozolomide—malignant glioma	0.000204	0.00154	CcSEcCtD
Citalopram—Oedema—Temozolomide—malignant glioma	0.000202	0.00152	CcSEcCtD
Citalopram—Anaphylactic shock—Temozolomide—malignant glioma	0.000202	0.00152	CcSEcCtD
Citalopram—Infection—Temozolomide—malignant glioma	0.000201	0.00151	CcSEcCtD
Citalopram—Anorexia—Carmustine—malignant glioma	0.000199	0.0015	CcSEcCtD
Citalopram—Nervous system disorder—Temozolomide—malignant glioma	0.000198	0.00149	CcSEcCtD
Citalopram—Thrombocytopenia—Temozolomide—malignant glioma	0.000198	0.00149	CcSEcCtD
Citalopram—Skin disorder—Temozolomide—malignant glioma	0.000196	0.00148	CcSEcCtD
Citalopram—Hypotension—Carmustine—malignant glioma	0.000195	0.00147	CcSEcCtD
Citalopram—Hyperhidrosis—Temozolomide—malignant glioma	0.000195	0.00147	CcSEcCtD
Citalopram—Anorexia—Temozolomide—malignant glioma	0.000193	0.00145	CcSEcCtD
Citalopram—ABCB1—midbrain—malignant glioma	0.000192	0.0043	CbGeAlD
Citalopram—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00019	0.00144	CcSEcCtD
Citalopram—Insomnia—Carmustine—malignant glioma	0.000189	0.00143	CcSEcCtD
Citalopram—Paraesthesia—Carmustine—malignant glioma	0.000188	0.00142	CcSEcCtD
Citalopram—ABCB1—spinal cord—malignant glioma	0.000188	0.0042	CbGeAlD
Citalopram—Dyspnoea—Carmustine—malignant glioma	0.000186	0.00141	CcSEcCtD
Citalopram—Somnolence—Carmustine—malignant glioma	0.000186	0.0014	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000184	0.00139	CcSEcCtD
Citalopram—Insomnia—Temozolomide—malignant glioma	0.000183	0.00138	CcSEcCtD
Citalopram—Decreased appetite—Carmustine—malignant glioma	0.000182	0.00137	CcSEcCtD
Citalopram—Paraesthesia—Temozolomide—malignant glioma	0.000181	0.00137	CcSEcCtD
Citalopram—Gastrointestinal disorder—Carmustine—malignant glioma	0.00018	0.00136	CcSEcCtD
Citalopram—Dyspnoea—Temozolomide—malignant glioma	0.00018	0.00136	CcSEcCtD
Citalopram—Somnolence—Temozolomide—malignant glioma	0.00018	0.00135	CcSEcCtD
Citalopram—Constipation—Carmustine—malignant glioma	0.000179	0.00135	CcSEcCtD
Citalopram—Pain—Carmustine—malignant glioma	0.000179	0.00135	CcSEcCtD
Citalopram—Dyspepsia—Temozolomide—malignant glioma	0.000178	0.00134	CcSEcCtD
Citalopram—Decreased appetite—Temozolomide—malignant glioma	0.000176	0.00132	CcSEcCtD
Citalopram—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000174	0.00132	CcSEcCtD
Citalopram—Fatigue—Temozolomide—malignant glioma	0.000174	0.00131	CcSEcCtD
Citalopram—Pain—Temozolomide—malignant glioma	0.000173	0.0013	CcSEcCtD
Citalopram—Constipation—Temozolomide—malignant glioma	0.000173	0.0013	CcSEcCtD
Citalopram—Feeling abnormal—Carmustine—malignant glioma	0.000172	0.0013	CcSEcCtD
Citalopram—Gastrointestinal pain—Carmustine—malignant glioma	0.000171	0.00129	CcSEcCtD
Citalopram—CYP2D6—brain—malignant glioma	0.000168	0.00376	CbGeAlD
Citalopram—Feeling abnormal—Temozolomide—malignant glioma	0.000166	0.00126	CcSEcCtD
Citalopram—Abdominal pain—Carmustine—malignant glioma	0.000165	0.00125	CcSEcCtD
Citalopram—Body temperature increased—Carmustine—malignant glioma	0.000165	0.00125	CcSEcCtD
Citalopram—Gastrointestinal pain—Temozolomide—malignant glioma	0.000165	0.00125	CcSEcCtD
Citalopram—Urticaria—Temozolomide—malignant glioma	0.00016	0.00121	CcSEcCtD
Citalopram—Abdominal pain—Temozolomide—malignant glioma	0.00016	0.0012	CcSEcCtD
Citalopram—Body temperature increased—Temozolomide—malignant glioma	0.00016	0.0012	CcSEcCtD
Citalopram—Hypersensitivity—Carmustine—malignant glioma	0.000154	0.00116	CcSEcCtD
Citalopram—ABCB1—central nervous system—malignant glioma	0.000152	0.0034	CbGeAlD
Citalopram—Asthenia—Carmustine—malignant glioma	0.00015	0.00113	CcSEcCtD
Citalopram—Hypersensitivity—Temozolomide—malignant glioma	0.000149	0.00112	CcSEcCtD
Citalopram—ABCB1—cerebellum—malignant glioma	0.000149	0.00333	CbGeAlD
Citalopram—Asthenia—Temozolomide—malignant glioma	0.000145	0.00109	CcSEcCtD
Citalopram—Diarrhoea—Carmustine—malignant glioma	0.000143	0.00108	CcSEcCtD
Citalopram—Pruritus—Temozolomide—malignant glioma	0.000143	0.00108	CcSEcCtD
Citalopram—Dizziness—Carmustine—malignant glioma	0.000138	0.00104	CcSEcCtD
Citalopram—Diarrhoea—Temozolomide—malignant glioma	0.000138	0.00104	CcSEcCtD
Citalopram—Dizziness—Temozolomide—malignant glioma	0.000134	0.00101	CcSEcCtD
Citalopram—Vomiting—Carmustine—malignant glioma	0.000133	0.001	CcSEcCtD
Citalopram—Rash—Carmustine—malignant glioma	0.000132	0.000994	CcSEcCtD
Citalopram—Dermatitis—Carmustine—malignant glioma	0.000132	0.000993	CcSEcCtD
Citalopram—Headache—Carmustine—malignant glioma	0.000131	0.000988	CcSEcCtD
Citalopram—Vomiting—Temozolomide—malignant glioma	0.000128	0.000969	CcSEcCtD
Citalopram—Rash—Temozolomide—malignant glioma	0.000127	0.000961	CcSEcCtD
Citalopram—Dermatitis—Temozolomide—malignant glioma	0.000127	0.00096	CcSEcCtD
Citalopram—Headache—Temozolomide—malignant glioma	0.000127	0.000955	CcSEcCtD
Citalopram—Nausea—Carmustine—malignant glioma	0.000124	0.000937	CcSEcCtD
Citalopram—ABCB1—brain—malignant glioma	0.000121	0.0027	CbGeAlD
Citalopram—Nausea—Temozolomide—malignant glioma	0.00012	0.000905	CcSEcCtD
Citalopram—HRH1—Signaling Pathways—TERT—malignant glioma	6.6e-06	0.000114	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TERT—malignant glioma	6.58e-06	0.000114	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOTCH1—malignant glioma	6.57e-06	0.000113	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL2—malignant glioma	6.5e-06	0.000112	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TERT—malignant glioma	6.48e-06	0.000112	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PDGFB—malignant glioma	6.45e-06	0.000111	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CD80—malignant glioma	6.43e-06	0.000111	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PDGFB—malignant glioma	6.43e-06	0.000111	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CG—malignant glioma	6.42e-06	0.000111	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APC—malignant glioma	6.42e-06	0.000111	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGFR1—malignant glioma	6.41e-06	0.000111	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGFR1—malignant glioma	6.39e-06	0.00011	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.39e-06	0.00011	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGF—malignant glioma	6.35e-06	0.00011	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PDGFB—malignant glioma	6.33e-06	0.000109	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HIF1A—malignant glioma	6.32e-06	0.000109	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTPN11—malignant glioma	6.31e-06	0.000109	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTP1—malignant glioma	6.3e-06	0.000109	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HIF1A—malignant glioma	6.3e-06	0.000109	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGFR1—malignant glioma	6.29e-06	0.000109	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CAV1—malignant glioma	6.24e-06	0.000108	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HIF1A—malignant glioma	6.2e-06	0.000107	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—BCHE—malignant glioma	6.17e-06	0.000107	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTP1—malignant glioma	6.15e-06	0.000106	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAT—malignant glioma	6.13e-06	0.000106	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CAV1—malignant glioma	6.12e-06	0.000106	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CAV1—malignant glioma	6.11e-06	0.000105	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SLC5A5—malignant glioma	6.09e-06	0.000105	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CAV1—malignant glioma	6.09e-06	0.000105	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KDR—malignant glioma	6.04e-06	0.000104	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—BRAF—malignant glioma	6.04e-06	0.000104	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KDR—malignant glioma	6.02e-06	0.000104	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CAV1—malignant glioma	5.99e-06	0.000104	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAT—malignant glioma	5.98e-06	0.000103	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KDR—malignant glioma	5.93e-06	0.000102	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT2—malignant glioma	5.88e-06	0.000101	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—malignant glioma	5.85e-06	0.000101	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—F2—malignant glioma	5.81e-06	0.0001	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FN1—malignant glioma	5.81e-06	0.0001	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FN1—malignant glioma	5.8e-06	0.0001	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—F2—malignant glioma	5.8e-06	0.0001	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTP1—malignant glioma	5.79e-06	0.0001	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NCOR1—malignant glioma	5.79e-06	0.0001	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.76e-06	9.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BAD—malignant glioma	5.75e-06	9.92e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BAD—malignant glioma	5.73e-06	9.89e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.71e-06	9.86e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FN1—malignant glioma	5.71e-06	9.85e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—F2—malignant glioma	5.71e-06	9.85e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOTCH1—malignant glioma	5.69e-06	9.83e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CG—malignant glioma	5.69e-06	9.82e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOTCH1—malignant glioma	5.67e-06	9.79e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NCOR1—malignant glioma	5.65e-06	9.76e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	5.64e-06	9.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAT—malignant glioma	5.64e-06	9.74e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BAD—malignant glioma	5.64e-06	9.74e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	5.59e-06	9.66e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOTCH1—malignant glioma	5.58e-06	9.64e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CD80—malignant glioma	5.57e-06	9.63e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CG—malignant glioma	5.57e-06	9.62e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APC—malignant glioma	5.56e-06	9.61e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CG—malignant glioma	5.56e-06	9.61e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CD80—malignant glioma	5.56e-06	9.6e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APC—malignant glioma	5.55e-06	9.58e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CG—malignant glioma	5.55e-06	9.58e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—malignant glioma	5.53e-06	9.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGF—malignant glioma	5.5e-06	9.5e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—malignant glioma	5.49e-06	9.48e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGF—malignant glioma	5.48e-06	9.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CD80—malignant glioma	5.47e-06	9.45e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTPN11—malignant glioma	5.47e-06	9.44e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTT1—malignant glioma	5.46e-06	9.44e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CG—malignant glioma	5.46e-06	9.43e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APC—malignant glioma	5.46e-06	9.43e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTPN11—malignant glioma	5.45e-06	9.41e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—FGF2—malignant glioma	5.4e-06	9.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGF—malignant glioma	5.4e-06	9.32e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—malignant glioma	5.38e-06	9.29e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTPN11—malignant glioma	5.36e-06	9.26e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NCOR1—malignant glioma	5.32e-06	9.19e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BRAF—malignant glioma	5.23e-06	9.03e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BRAF—malignant glioma	5.21e-06	9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—malignant glioma	5.13e-06	8.86e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS1—malignant glioma	5.12e-06	8.84e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT2—malignant glioma	5.09e-06	8.79e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	5.08e-06	8.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT2—malignant glioma	5.07e-06	8.76e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—malignant glioma	5.07e-06	8.75e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MDM2—malignant glioma	5.06e-06	8.73e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—malignant glioma	5.05e-06	8.73e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RAF1—malignant glioma	5.04e-06	8.7e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—malignant glioma	5e-06	8.64e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT2—malignant glioma	5e-06	8.63e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—malignant glioma	4.99e-06	8.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.98e-06	8.6e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—malignant glioma	4.97e-06	8.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	4.92e-06	8.5e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—malignant glioma	4.91e-06	8.48e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—malignant glioma	4.9e-06	8.46e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—malignant glioma	4.89e-06	8.45e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—malignant glioma	4.88e-06	8.42e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—malignant glioma	4.84e-06	8.37e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—malignant glioma	4.83e-06	8.34e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—malignant glioma	4.8e-06	8.29e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—malignant glioma	4.79e-06	8.27e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAT—malignant glioma	4.78e-06	8.25e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—malignant glioma	4.77e-06	8.24e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—BCHE—malignant glioma	4.76e-06	8.22e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—malignant glioma	4.75e-06	8.21e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—malignant glioma	4.73e-06	8.17e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAV1—malignant glioma	4.72e-06	8.15e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A5—malignant glioma	4.7e-06	8.12e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—malignant glioma	4.7e-06	8.12e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGF2—malignant glioma	4.68e-06	8.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGF2—malignant glioma	4.67e-06	8.06e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAV1—malignant glioma	4.61e-06	7.95e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGF2—malignant glioma	4.6e-06	7.94e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	4.57e-06	7.89e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—malignant glioma	4.53e-06	7.82e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—malignant glioma	4.52e-06	7.8e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NCOR1—malignant glioma	4.51e-06	7.79e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.51e-06	7.79e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—malignant glioma	4.4e-06	7.6e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—malignant glioma	4.39e-06	7.57e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—malignant glioma	4.38e-06	7.57e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—malignant glioma	4.37e-06	7.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RAF1—malignant glioma	4.37e-06	7.54e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—malignant glioma	4.36e-06	7.53e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RAF1—malignant glioma	4.35e-06	7.52e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAV1—malignant glioma	4.34e-06	7.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—malignant glioma	4.32e-06	7.46e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—malignant glioma	4.32e-06	7.46e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	4.32e-06	7.46e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—malignant glioma	4.31e-06	7.44e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—malignant glioma	4.3e-06	7.43e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—malignant glioma	4.3e-06	7.42e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RAF1—malignant glioma	4.29e-06	7.4e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—malignant glioma	4.28e-06	7.39e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—malignant glioma	4.27e-06	7.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—malignant glioma	4.26e-06	7.36e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—malignant glioma	4.25e-06	7.34e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—malignant glioma	4.25e-06	7.34e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	4.24e-06	7.32e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—malignant glioma	4.23e-06	7.3e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—malignant glioma	4.2e-06	7.25e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	4.18e-06	7.23e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—malignant glioma	4.15e-06	7.16e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—malignant glioma	4.15e-06	7.16e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—malignant glioma	4.1e-06	7.08e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—malignant glioma	4.08e-06	7.05e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—malignant glioma	4.05e-06	6.99e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	4.02e-06	6.94e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—malignant glioma	3.96e-06	6.84e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—malignant glioma	3.95e-06	6.83e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	3.95e-06	6.81e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—malignant glioma	3.92e-06	6.77e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—malignant glioma	3.92e-06	6.76e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—malignant glioma	3.91e-06	6.75e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—malignant glioma	3.9e-06	6.74e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	3.88e-06	6.71e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—malignant glioma	3.85e-06	6.65e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—malignant glioma	3.84e-06	6.64e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—malignant glioma	3.84e-06	6.63e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—malignant glioma	3.82e-06	6.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—malignant glioma	3.8e-06	6.57e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—malignant glioma	3.79e-06	6.54e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—malignant glioma	3.78e-06	6.53e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—malignant glioma	3.77e-06	6.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—malignant glioma	3.71e-06	6.4e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—malignant glioma	3.69e-06	6.38e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—malignant glioma	3.69e-06	6.37e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—malignant glioma	3.69e-06	6.37e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAT—malignant glioma	3.69e-06	6.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—malignant glioma	3.68e-06	6.36e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAV1—malignant glioma	3.68e-06	6.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—malignant glioma	3.67e-06	6.34e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—malignant glioma	3.64e-06	6.28e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—malignant glioma	3.62e-06	6.24e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—malignant glioma	3.59e-06	6.21e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—malignant glioma	3.58e-06	6.19e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—malignant glioma	3.53e-06	6.1e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	3.53e-06	6.09e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.51e-06	6.07e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOR1—malignant glioma	3.48e-06	6.01e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—malignant glioma	3.48e-06	6e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—malignant glioma	3.46e-06	5.97e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—malignant glioma	3.35e-06	5.78e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—malignant glioma	3.33e-06	5.75e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—malignant glioma	3.32e-06	5.73e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—malignant glioma	3.29e-06	5.69e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—malignant glioma	3.29e-06	5.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—malignant glioma	3.28e-06	5.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	3.27e-06	5.64e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—malignant glioma	3.26e-06	5.64e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—malignant glioma	3.26e-06	5.64e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—malignant glioma	3.23e-06	5.58e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—malignant glioma	3.23e-06	5.58e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—malignant glioma	3.21e-06	5.55e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—malignant glioma	3.19e-06	5.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—malignant glioma	3.06e-06	5.29e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—malignant glioma	3.05e-06	5.27e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.03e-06	5.23e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—malignant glioma	3e-06	5.19e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—malignant glioma	3e-06	5.18e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	3e-06	5.18e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—malignant glioma	2.99e-06	5.17e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—malignant glioma	2.98e-06	5.16e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.94e-06	5.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—malignant glioma	2.94e-06	5.07e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—malignant glioma	2.9e-06	5.01e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—malignant glioma	2.85e-06	4.91e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAV1—malignant glioma	2.84e-06	4.9e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—malignant glioma	2.83e-06	4.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—malignant glioma	2.82e-06	4.87e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—malignant glioma	2.78e-06	4.8e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—malignant glioma	2.78e-06	4.79e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—malignant glioma	2.66e-06	4.59e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—malignant glioma	2.62e-06	4.52e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—malignant glioma	2.6e-06	4.49e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—malignant glioma	2.6e-06	4.49e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	2.59e-06	4.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.58e-06	4.46e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.57e-06	4.43e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	2.55e-06	4.4e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—malignant glioma	2.54e-06	4.39e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—malignant glioma	2.51e-06	4.34e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—malignant glioma	2.51e-06	4.33e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—malignant glioma	2.49e-06	4.31e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—malignant glioma	2.47e-06	4.26e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—malignant glioma	2.45e-06	4.23e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.27e-06	3.92e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—malignant glioma	2.22e-06	3.83e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—malignant glioma	2.17e-06	3.75e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—malignant glioma	2.13e-06	3.67e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—malignant glioma	2.12e-06	3.67e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—malignant glioma	2.12e-06	3.65e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—malignant glioma	2.08e-06	3.6e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—malignant glioma	2.01e-06	3.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.98e-06	3.42e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—malignant glioma	1.96e-06	3.39e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—malignant glioma	1.96e-06	3.38e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.85e-06	3.19e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—malignant glioma	1.71e-06	2.96e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—malignant glioma	1.64e-06	2.83e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—malignant glioma	1.6e-06	2.76e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.56e-06	2.7e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—malignant glioma	1.51e-06	2.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—malignant glioma	1.28e-06	2.21e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.21e-06	2.09e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—malignant glioma	9.86e-07	1.7e-05	CbGpPWpGaD
